JP2017526339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526339A5 JP2017526339A5 JP2016573964A JP2016573964A JP2017526339A5 JP 2017526339 A5 JP2017526339 A5 JP 2017526339A5 JP 2016573964 A JP2016573964 A JP 2016573964A JP 2016573964 A JP2016573964 A JP 2016573964A JP 2017526339 A5 JP2017526339 A5 JP 2017526339A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- domain
- axl
- seq
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 238000000034 method Methods 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000037819 metastatic cancer Diseases 0.000 claims 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 3
- 230000002018 overexpression Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- -1 DVD-lg Proteins 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 101000973901 Homo sapiens Tyrosine-protein kinase Mer Proteins 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 101150098329 Tyro3 gene Proteins 0.000 claims 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
- 102000045684 human MERTK Human genes 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1410825.2 | 2014-06-18 | ||
| GBGB1410825.2A GB201410825D0 (en) | 2014-06-18 | 2014-06-18 | Anti-axl antibodies |
| PCT/EP2015/063704 WO2015193430A1 (en) | 2014-06-18 | 2015-06-18 | Anti-axl antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526339A JP2017526339A (ja) | 2017-09-14 |
| JP2017526339A5 true JP2017526339A5 (2) | 2018-05-10 |
| JP6787796B2 JP6787796B2 (ja) | 2020-11-18 |
Family
ID=51266760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573964A Active JP6787796B2 (ja) | 2014-06-18 | 2015-06-18 | 抗Ａｘｌ抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9975953B2 (2) |
| EP (1) | EP3157575B1 (2) |
| JP (1) | JP6787796B2 (2) |
| KR (1) | KR102408356B1 (2) |
| CN (2) | CN113321732B (2) |
| AU (1) | AU2015276155B2 (2) |
| CA (1) | CA2952113A1 (2) |
| GB (1) | GB201410825D0 (2) |
| MX (1) | MX375524B (2) |
| WO (1) | WO2015193430A1 (2) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410826D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| SMT202000265T1 (it) | 2014-07-11 | 2020-07-08 | Genmab As | Anticorpi che legano axl |
| JP6864953B2 (ja) * | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ａｘｌに対するヒトモノクローナル抗体 |
| AU2015366213B2 (en) * | 2014-12-18 | 2021-10-07 | Bergenbio Asa | Anti-Axl antagonistic antibodies |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| PL3319993T3 (pl) * | 2015-07-10 | 2020-07-27 | Genmab A/S | Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka |
| SMT202600033T1 (it) | 2016-04-15 | 2026-03-09 | Bioatla Inc | Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi |
| GB201610902D0 (en) | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CN107973854B (zh) * | 2017-12-11 | 2021-05-04 | 苏州银河生物医药有限公司 | Pdl1单克隆抗体及其应用 |
| CA3095986A1 (en) * | 2018-04-10 | 2019-10-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
| US20210215697A1 (en) * | 2018-05-14 | 2021-07-15 | Bergenbio Asa | Serum Biomarkers |
| CN110540592B (zh) * | 2018-05-29 | 2022-08-09 | 杭州尚健生物技术有限公司 | 结合axl蛋白的抗体及其应用 |
| CN112955240B (zh) * | 2018-10-25 | 2022-09-16 | 豪夫迈·罗氏有限公司 | 抗体FcRn结合的修饰 |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| EP4132652A1 (en) | 2020-04-08 | 2023-02-15 | BerGenBio ASA | Axl inhibitors for antiviral therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| EP4286406A4 (en) | 2021-01-29 | 2025-07-23 | Illimis Therapeutics Inc | FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| CN113444180B (zh) * | 2021-06-16 | 2023-03-31 | 上海鑫湾生物科技有限公司 | 靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5769969B2 (ja) | 2007-11-12 | 2015-08-26 | ユー３・ファーマ・ゲーエムベーハー | Ａｘｌ抗体 |
| AU2008321835B2 (en) | 2007-11-15 | 2014-11-20 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
| KR20120024763A (ko) | 2009-05-15 | 2012-03-14 | 추가이 세이야쿠 가부시키가이샤 | 항ａｘｌ 항체 |
| TW201106972A (en) * | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| RU2577986C2 (ru) * | 2010-06-18 | 2016-03-20 | Дженентек, Инк. | Антитела против axl и способы их применения |
| ES2677367T3 (es) | 2011-06-22 | 2018-08-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticuerpos anti-Axl y usos de los mismos |
| CA2839508A1 (en) * | 2011-06-22 | 2012-12-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| EP3590538A1 (en) * | 2011-12-05 | 2020-01-08 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) |
| GB201410826D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| AU2015366213B2 (en) * | 2014-12-18 | 2021-10-07 | Bergenbio Asa | Anti-Axl antagonistic antibodies |
-
2014
- 2014-06-18 GB GBGB1410825.2A patent/GB201410825D0/en not_active Ceased
-
2015
- 2015-06-18 CA CA2952113A patent/CA2952113A1/en active Pending
- 2015-06-18 JP JP2016573964A patent/JP6787796B2/ja active Active
- 2015-06-18 EP EP15729850.6A patent/EP3157575B1/en active Active
- 2015-06-18 US US15/318,023 patent/US9975953B2/en active Active
- 2015-06-18 WO PCT/EP2015/063704 patent/WO2015193430A1/en not_active Ceased
- 2015-06-18 CN CN202110419463.1A patent/CN113321732B/zh active Active
- 2015-06-18 MX MX2016016886A patent/MX375524B/es active IP Right Grant
- 2015-06-18 AU AU2015276155A patent/AU2015276155B2/en not_active Ceased
- 2015-06-18 CN CN201580042718.XA patent/CN106573980B/zh active Active
- 2015-06-18 KR KR1020177001481A patent/KR102408356B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526339A5 (2) | ||
| JP2017519501A5 (2) | ||
| JP7334177B2 (ja) | 抗ｃｄ７３抗体及びその使用 | |
| WO2020114480A1 (en) | Anti-claudin antibodies and uses thereof | |
| JP2018506961A5 (2) | ||
| JP2017535257A5 (2) | ||
| JP2017529838A5 (2) | ||
| JP6608698B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| CN112646031A (zh) | 抗4-1bb纳米抗体及其用途 | |
| JP2013527761A5 (2) | ||
| JP2012521217A5 (2) | ||
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| JP2018500014A5 (2) | ||
| JP2016536342A5 (2) | ||
| JP2017522903A5 (2) | ||
| JP2012100677A5 (2) | ||
| JP2013519364A5 (2) | ||
| KR20230016186A (ko) | 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법 | |
| JP2019534705A5 (2) | ||
| JP2011501656A5 (2) | ||
| CN114502591A (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP2015503909A5 (2) | ||
| JP2022533538A5 (2) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2017521054A5 (2) |